Logo image of NMTC

NEUROONE MEDICAL TECHNOLOGIE (NMTC) Stock Fundamental Analysis

USA - NASDAQ:NMTC - US64130M2098 - Common Stock

0.8891 USD
-0.01 (-0.58%)
Last: 9/12/2025, 4:30:02 PM
0.8798 USD
-0.01 (-1.05%)
After Hours: 9/12/2025, 4:30:02 PM
Fundamental Rating

3

NMTC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 190 industry peers in the Health Care Equipment & Supplies industry. The financial health of NMTC is average, but there are quite some concerns on its profitability. NMTC is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NMTC had negative earnings in the past year.
NMTC had a negative operating cash flow in the past year.
In the past 5 years NMTC always reported negative net income.
In the past 5 years NMTC always reported negative operating cash flow.
NMTC Yearly Net Income VS EBIT VS OCF VS FCFNMTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of NMTC (-49.33%) is worse than 66.84% of its industry peers.
The Return On Equity of NMTC (-65.26%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -49.33%
ROE -65.26%
ROIC N/A
ROA(3y)-151.29%
ROA(5y)-173.14%
ROE(3y)-597.5%
ROE(5y)-520.67%
ROIC(3y)N/A
ROIC(5y)N/A
NMTC Yearly ROA, ROE, ROICNMTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K -2K

1.3 Margins

Looking at the Gross Margin, with a value of 70.14%, NMTC belongs to the top of the industry, outperforming 80.53% of the companies in the same industry.
NMTC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.14%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NMTC Yearly Profit, Operating, Gross MarginsNMTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

4

2. Health

2.1 Basic Checks

NMTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NMTC has been increased compared to 1 year ago.
Compared to 5 years ago, NMTC has more shares outstanding
The debt/assets ratio for NMTC is higher compared to a year ago.
NMTC Yearly Shares OutstandingNMTC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
NMTC Yearly Total Debt VS Total AssetsNMTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

NMTC has an Altman-Z score of 0.32. This is a bad value and indicates that NMTC is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of NMTC (0.32) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.13 indicates that NMTC is not too dependend on debt financing.
NMTC has a Debt to Equity ratio of 0.13. This is comparable to the rest of the industry: NMTC outperforms 59.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z 0.32
ROIC/WACCN/A
WACC8.57%
NMTC Yearly LT Debt VS Equity VS FCFNMTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 7.13 indicates that NMTC has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 7.13, NMTC belongs to the top of the industry, outperforming 86.84% of the companies in the same industry.
NMTC has a Quick Ratio of 5.80. This indicates that NMTC is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 5.80, NMTC belongs to the best of the industry, outperforming 84.74% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.13
Quick Ratio 5.8
NMTC Yearly Current Assets VS Current LiabilitesNMTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

7

3. Growth

3.1 Past

NMTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.67%, which is quite impressive.
Looking at the last year, NMTC shows a very strong growth in Revenue. The Revenue has grown by 142.96%.
Measured over the past years, NMTC shows a very strong growth in Revenue. The Revenue has been growing by 143.22% on average per year.
EPS 1Y (TTM)67.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.1%
Revenue 1Y (TTM)142.96%
Revenue growth 3Y143.22%
Revenue growth 5YN/A
Sales Q2Q%105.38%

3.2 Future

Based on estimates for the next years, NMTC will show a very strong growth in Earnings Per Share. The EPS will grow by 20.23% on average per year.
The Revenue is expected to grow by 34.68% on average over the next years. This is a very strong growth
EPS Next Y69.05%
EPS Next 2Y28.17%
EPS Next 3Y20.23%
EPS Next 5YN/A
Revenue Next Year24.29%
Revenue Next 2Y33.1%
Revenue Next 3Y35.46%
Revenue Next 5Y34.68%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NMTC Yearly Revenue VS EstimatesNMTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 5M 10M 15M 20M
NMTC Yearly EPS VS EstimatesNMTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NMTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NMTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NMTC Price Earnings VS Forward Price EarningsNMTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NMTC Per share dataNMTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1

4.3 Compensation for Growth

A more expensive valuation may be justified as NMTC's earnings are expected to grow with 20.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.17%
EPS Next 3Y20.23%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NMTC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROONE MEDICAL TECHNOLOGIE

NASDAQ:NMTC (9/12/2025, 4:30:02 PM)

After market: 0.8798 -0.01 (-1.05%)

0.8891

-0.01 (-0.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)12-15 2025-12-15/amc
Inst Owners10.96%
Inst Owner Change600.36%
Ins Owners4.25%
Ins Owner Change4.43%
Market Cap44.45M
Analysts85.71
Price Target1.48 (66.46%)
Short Float %0.49%
Short Ratio0.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.46%
Min EPS beat(2)23.75%
Max EPS beat(2)41.18%
EPS beat(4)3
Avg EPS beat(4)47.24%
Min EPS beat(4)-34.8%
Max EPS beat(4)158.82%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-25.92%
Min Revenue beat(2)-43.22%
Max Revenue beat(2)-8.62%
Revenue beat(4)1
Avg Revenue beat(4)-21.92%
Min Revenue beat(4)-88.49%
Max Revenue beat(4)52.66%
Revenue beat(8)2
Avg Revenue beat(8)-19.9%
Revenue beat(12)4
Avg Revenue beat(12)-5.35%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)33.33%
EPS NY rev (1m)0%
EPS NY rev (3m)7.14%
Revenue NQ rev (1m)-1.36%
Revenue NQ rev (3m)-26.67%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)6.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.62
P/FCF N/A
P/OCF N/A
P/B 5.44
P/tB 5.47
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0.19
BVpS0.16
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -49.33%
ROE -65.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.14%
FCFM N/A
ROA(3y)-151.29%
ROA(5y)-173.14%
ROE(3y)-597.5%
ROE(5y)-520.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.13%
Cap/Sales 1.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.13
Quick Ratio 5.8
Altman-Z 0.32
F-Score5
WACC8.57%
ROIC/WACCN/A
Cap/Depr(3y)158.25%
Cap/Depr(5y)160.45%
Cap/Sales(3y)9.28%
Cap/Sales(5y)12.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.1%
EPS Next Y69.05%
EPS Next 2Y28.17%
EPS Next 3Y20.23%
EPS Next 5YN/A
Revenue 1Y (TTM)142.96%
Revenue growth 3Y143.22%
Revenue growth 5YN/A
Sales Q2Q%105.38%
Revenue Next Year24.29%
Revenue Next 2Y33.1%
Revenue Next 3Y35.46%
Revenue Next 5Y34.68%
EBIT growth 1Y53.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y56.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.54%
OCF growth 3YN/A
OCF growth 5YN/A